All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Bookmark this article
On September 19, 2022, it was announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) had issued a positive opinion for the Bruton’s tyrosine kinase inhibitor zanubrutinib for the treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based therapy.1 This announcement is based on key data obtained from the phase II MAGNOLIA trial (NCT03846427).1
The MAGNOLIA trial reported an overall response rate of 68% (95% CI, 55.6–79.1), a complete response rate of 26%, and a partial response rate of 42%.1 The median time to response was 2.8 months. Extranodal, nodal, splenic, and unknown MZL subtypes demonstrated overall response rates of 64%, 76%, 67%, and 50%, respectively. In addition, zanubrutinib demonstrated an acceptable safety profile, consistent with previous studies.1
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Phase II MAGNOLIA trial: Efficacy and safety of zanubrutinib in marginal zone lymphoma
Bruton’s tyrosine kinase (BTK) inhibitors provide a highly selective mechanism of action in marginal zone lymphoma (MZL), targeting B-cell receptor signaling...
Novel targeted therapies for R/R marginal zone lymphoma
It has been challenging to define an optimal therapeutic approach for relapsed patients with marginal zone lymphoma (MZL) due to disease heterogeneity, especially in the advanced, refractory...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox